State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETFXPH
Type
ETF
Peer group
US equity: Healthcare
Net assets
$307.9M
Expense ratio
0.35%
1-year return
+49.6%
3 years, a year
+18.7%
5 years, a year
+9.1%
12-month yield
0.41%
Holdings
62
What it aims to do.
The State Street SPDR S&P Pharmaceuticals ETF (the Fund) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| State Street Global Advisors | 7.93% |
| ELVN Enliven Therapeutics Inc | 2.45% |
| CORT Corcept Therapeutics Inc | 2.29% |
| Terns Pharmaceuticals Inc | 2.16% |
| JOBY Perrigo Co PLC | 2.10% |
| AXSM Axsome Therapeutics Inc | 2.03% |
| INVA Innoviva Inc | 1.99% |
| MRK Merck & Co Inc | 1.98% |
| PFE Pfizer Inc | 1.97% |
| JOBY Royalty Pharma PLC | 1.97% |
More on XPH.
- XPH overview
- XPH holdings
- XPH risk
- XPH costs
- XPH money in and out
- XPH share classes
- Compare XPH with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.